Latest News & Features
article
Canada has a robust and reliable framework for resolving IP disputes, and it shouldn’t be ignored by litigants, say Ron Dimock, Sangeetha Punniyamoorthy and Nikolas Purcell of DLA Piper. 2 October 2017
Americas
Hospira has appealed against a verdict which saw Amgen secure $70 million in damages over a biosimilar dispute between the two companies. 2 October 2017
Big Pharma
The European Medicines Agency (EMA) has claimed that relocation to eight unidentified cities would result in “permanent damage to the system”. 29 September 2017
Americas
AbbVie has settled its patent dispute over Amgen’s proposed biosimilar for Humira (adalimumab), a drug used to treat multiple types of arthritis as well as psoriasis. 29 September 2017
Americas
Unlike in Europe, the lack of a plausibility threshold in the US means that those applying for patents there are more likely to be granted a broader claim. 28 September 2017
Americas
UK-based Indivior, a company that specialises in addiction treatment drugs, has settled a dispute with generic manufacturer Mylan. 28 September 2017
Big Pharma
The UK’s House of Commons has launched an investigation into post-Brexit regulatory agreements needed to guarantee the safe and effective supply of medicines and medical devices. 27 September 2017
Africa
Interpol has seized more than $51 million worth of potentially dangerous medicines in its latest operation. 27 September 2017
Americas
The Saint Regis Mohawk Tribe has attempted to dismiss inter partes reviews brought by Mylan. 26 September 2017
Americas
Amgen has secured $70 million in damages from a jury in a biosimilar dispute with Hospira. 26 September 2017